Hamburg-based Evotec extends collaboration with British AI firm

Hamburg-based Evotec is to invest 15 million euros ($18 million) in the UK’s Exscientia, a company focused on artificial intelligence-driven drug discovery.

The investment is intended to facilitate the growth of the Dundee-based firm, and will expand an existing partnership to discover novel immuno-oncology therapeutics.

The money comes from a new 75 million euro loan facility the German firm has been provided with, from the European Investment Bank.